 smithkline ltskb aims 10 pct earnings raise smithkline beckman corp pursuing threepoint stragey achieve 10 pct annual increase operating earnings remainder decade 1986 smithkline earned 5211 mln dlrs 678 dlrs share revenues 36 billion dlrs company annual report nonpharmaceutical business play major role meeting earnings growth target fact grow faster pharmaceutical business smithkline major product antiulcer medication tagamet report intends improve earnings existing products expand product portfolio optimize financial resources bolster position antiulcer market tagamet met stiff competition smithkline strategy develop overthecounter version tagamet bolstered joint ventures ltwellcome plc pending venture japan smithkline allergan eye skin care products division billion dlr organization years grow 10 pct annually nondilutive acquisitions real possibility gavin herbert president eye skin care product group report 1986 allergan worldwide sales 433 mln dlrs smith kline french laboratories pharmaceuticals unit 1986 sales 19 billion dlrs file food drug administration marketing approval number cardiovascular agents including tissue plasminogen activator years sk fs sales force 20 pct larger 1987 1000 sales personnel smith kline small clinical laboratory testing unit 1986 sales 373 mln dlrs performs 24 mln tests year sees increases employee drug testing testing aids antibody smith kline depending share price cost money buy back shares years bought back 25 pct shares smithkline begins year management team including chief operating officer george ebright